DURHAM, N.C.--(BUSINESS WIRE)--Istari Oncology, Inc., a clinical-stage biotechnology company today announced that Jamie Iudica has joined as Chief Manufacturing Officer (CMO). Iudica brings more than 25 years of experience in the pharmaceutical industry to Istari, including leadership roles in engineering, manufacturing, and supply chain operations. His extensive expertise in vaccine drug substance and drug product manufacturing will be integral in rounding out the technical strength of the Istari team.
“We are excited to have Jamie join our leadership team as we continue to advance our PVSRIPO clinical platform across multiple indications for complex tumors,” said Matt Stober, President and CEO of Istari Oncology. “His deep technical experience in biologics, drug substance, and product manufacturing, including third-party manufacturing, will be invaluable as we continue to rapidly move through product development and subsequent launches.”
Iudica joins Istari from Xellia Pharmaceuticals, where he was their Senior Vice President, Global Product Supply, overseeing all aspects of global operations, including manufacturing and supply chain operations. Before his time at Xellia, Iudica served as Vice President, Global Biologics Operations at Pfizer, where he served as site leader for manufacturing operations for three commercial biosimilars. He also previously worked for Hospira, a leading provider of injectable drugs and infusion technologies, prior to its acquisition by Pfizer in 2015.
Iudica holds both a B.A. in Chemical Engineering and an MBA from Villanova University in Philadelphia, PA. He joins Istari’s growing leadership team signaling the company’s continued growth and expansion since 2020.
For more information about Istari Oncology and their ongoing clinical trials and research in PVSRIPO, visit www.istarioncology.com.
About Istari Oncology
Istari Oncology, Inc., headquartered in Research Triangle Park, North Carolina, is a privately-held clinical-stage biotechnology company focused on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. The company was founded by Darell Bigner, MD, PhD and Matthias Gromeier, MD, of Duke University Medical Center in 2016. Istari licensed a broad range of patents and patent applications from Duke University and has access to additional intellectual property to continue clinical and commercial development of these technologies. The company’s primary platform currently in clinical development is PVSRIPO. For more information, please visit: www.istarioncology.com.
